Company Overview
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.
Recent News
SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports
SCYNEXIS Reports First Quarter 2024 Financial ResultsĀ and Provides Corporate Update
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
Stock Overview
Symbol
SCYX
Exchange
Nasdaq
Market Cap
79.72m
Last Price
$2.11
52-Week Range
$1.35 - $3.87
07/26/2024 04:00 PM EDT